D-0486-2026 Class II Ongoing

Recalled by Leading Pharma, LLC — Fairfield, NJ

FDA drug recall D-0486-2026 was initiated by Leading Pharma, LLC on Mar 20, 2026 and is designated Class II. Reason for recall: CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit. The recall status is ongoing. Affected quantity: 9384 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 29, 2026
Initiation Date
Mar 20, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9384 bottles

Product description

Furosemide Tablets, USP, 80 mg, 100 Tablets bottles, Rx only, Manufactured by: Leading Pharma, LLC, Fairfield, NJ 07004, NDC 69315-118-01

Reason for recall

CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.

Distribution pattern

US Nationwide.

Code information

Lots# H03125, H03225, H03325, Exp Date: 2027/08

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0486-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0486-2026. Report a data issue: hello@regdatalab.com.